Bausch Health Cos. Inc.: Billionaire's Bet on Healthcare Conglomerate

Bausch Health Cos. Inc. $BHC, formerly known as Valeant Pharmaceuticals, is attracting the attention of billionaires eyeing the healthcare company's potential for significant growth. BHC owns 88% of its subsidiary Bausch + Lomb $BLCOand has stakes in other companies such as Salix and Solta Medical.

High debt and high potential

$BHC faces high debt of $21.2 billion, while its equity is only $2.9 billion. This financial pressure creates a highly leveraged position that can have a significant impact on the company's stock value. Every 1% increase in the company's value theoretically means an 8.6% increase in its equity.

The sale of BLCO as a key catalyst

A key factor that can deliver a huge boost to $BHCs stock value is the potential sale of its BLCO subsidiary. In the event that BLCO is sold for a higher than expected value, it could have a major impact on $BHCs financial position . This move would not only reduce debt but also increase the value of the company's remaining assets.

Billionaire interest and growth expectations

The data points to large cluster purchases of $BHCstock , with investments coming from some of the leading billionaires. It is expected that once the deal to sell $BLCO is finalized , BHC could become a typical example of a "sum of the parts" play, which could lead to significant growth in the company's stock value.